Loading…

Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement

Engaging patients as partners in biomedical research has gradually gained consensus over the last two decades. They provide a different perspective on health priorities and help to improve design and outcomes of clinical studies. This paper describes the relationship established between scientists a...

Full description

Saved in:
Bibliographic Details
Published in:Prion 2022-12, Vol.16 (1), p.66-77
Main Authors: Forloni, Gianluigi, Roiter, Ignazio, Artuso, Vladimiro, Marcon, Manuel, Colesso, Walter, Luban, Elviana, Lucca, Ugo, Tettamanti, Mauro, Pupillo, Elisabetta, Redaelli, Veronica, Mariuzzo, Francesco, Boscolo Buleghin, Giulia, Mariuzzo, Alice, Tagliavini, Fabrizio, Chiesa, Roberto, Ambrosini, Anna
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c534t-a1417623d362f0f061cc277d1b0984d42b02aee849de7d1e0cd024c8c31ff5d73
cites cdi_FETCH-LOGICAL-c534t-a1417623d362f0f061cc277d1b0984d42b02aee849de7d1e0cd024c8c31ff5d73
container_end_page 77
container_issue 1
container_start_page 66
container_title Prion
container_volume 16
creator Forloni, Gianluigi
Roiter, Ignazio
Artuso, Vladimiro
Marcon, Manuel
Colesso, Walter
Luban, Elviana
Lucca, Ugo
Tettamanti, Mauro
Pupillo, Elisabetta
Redaelli, Veronica
Mariuzzo, Francesco
Boscolo Buleghin, Giulia
Mariuzzo, Alice
Tagliavini, Fabrizio
Chiesa, Roberto
Ambrosini, Anna
description Engaging patients as partners in biomedical research has gradually gained consensus over the last two decades. They provide a different perspective on health priorities and help to improve design and outcomes of clinical studies. This paper describes the relationship established between scientists and members of a large family at genetic risk of very rare lethal disease, fatal familial insomnia (FFI). This interaction led to a clinical trial based on the repurposing of doxycycline - an antibiotic with a known safety profile and optimal blood-brain barrier passage - which in numerous preclinical and clinical studies had given evidence of its potential therapeutic effect in neurodegenerative disorders, including prion diseases like FFI. The design of this trial posed several challenges, which were addressed jointly by the scientists and the FFI family. Potential participants excluded the possibility of being informed of their own FFI genotype; thus, the trial design had to include both carriers of the FFI mutation (10 subjects), and non-carriers (15 subjects), who were given placebo. Periodic clinical controls were performed on both groups by blinded examiners. The lack of surrogate outcome measures of treatment efficacy has required to compare the incidence of the disease in the treated group with a historical dataset during 10 years of observation. The trial is expected to end in 2023. Regardless of the clinical outcome, it will provide worthwhile knowledge on the disease. It also offers an important example of public engagement and collaboration to improve the quality of clinical science.
doi_str_mv 10.1080/19336896.2022.2083435
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9235883</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_bf4b361525114e5d97ad42e5fbfca978</doaj_id><sourcerecordid>2681036377</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-a1417623d362f0f061cc277d1b0984d42b02aee849de7d1e0cd024c8c31ff5d73</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhlcIREvhJ4B85JLWH-tdLwdEVQGtVAkOIHGzZu1x6uC1g70J6r_HIUlFL1zs0cw778zoaZrXjJ4zqugFG4To1NCdc8p5fZRohXzSnO7yi26gP54e4yo6aV6UsqJUDpyL582JkL3oezmcNuVrxi3G2W-RrO8gT2BSSEtvIJA5I8xTLRIfSdmMKzRzITCT7MtP4lImDuaqczD54GvgY0lT9PCOFOMxGiQQLVlvxuANwbiEJe7sXjbPHISCrw7_WfP908dvV9eL2y-fb64ubxdGinZeAGtZ33FhRccddbRjxvC-t2ykg2pty0fKAVG1g8WaRWos5a1RRjDnpO3FWXOz97UJVnqd_QT5Xifw-m8i5aWGPHsTUI-uHUXHJJeMtSjt0EMdgNKNzsDQq-r1fu9Vr5nQmnpGhvDI9HEl-ju9TFs9cCGVEtXg7cEgp18bLLOefDEYAkRMm6J5pxgVXcVSpXIvNTmVktE9jGFU7-DrI3y9g68P8Gvfm393fOg60q6CD3uBj5XeBL9TDlbPcB9Sdhmi8UWL_8_4A5EmwY8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2681036377</pqid></control><display><type>article</type><title>Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement</title><source>Taylor &amp; Francis Open Access</source><source>PubMed Central</source><creator>Forloni, Gianluigi ; Roiter, Ignazio ; Artuso, Vladimiro ; Marcon, Manuel ; Colesso, Walter ; Luban, Elviana ; Lucca, Ugo ; Tettamanti, Mauro ; Pupillo, Elisabetta ; Redaelli, Veronica ; Mariuzzo, Francesco ; Boscolo Buleghin, Giulia ; Mariuzzo, Alice ; Tagliavini, Fabrizio ; Chiesa, Roberto ; Ambrosini, Anna</creator><creatorcontrib>Forloni, Gianluigi ; Roiter, Ignazio ; Artuso, Vladimiro ; Marcon, Manuel ; Colesso, Walter ; Luban, Elviana ; Lucca, Ugo ; Tettamanti, Mauro ; Pupillo, Elisabetta ; Redaelli, Veronica ; Mariuzzo, Francesco ; Boscolo Buleghin, Giulia ; Mariuzzo, Alice ; Tagliavini, Fabrizio ; Chiesa, Roberto ; Ambrosini, Anna</creatorcontrib><description>Engaging patients as partners in biomedical research has gradually gained consensus over the last two decades. They provide a different perspective on health priorities and help to improve design and outcomes of clinical studies. This paper describes the relationship established between scientists and members of a large family at genetic risk of very rare lethal disease, fatal familial insomnia (FFI). This interaction led to a clinical trial based on the repurposing of doxycycline - an antibiotic with a known safety profile and optimal blood-brain barrier passage - which in numerous preclinical and clinical studies had given evidence of its potential therapeutic effect in neurodegenerative disorders, including prion diseases like FFI. The design of this trial posed several challenges, which were addressed jointly by the scientists and the FFI family. Potential participants excluded the possibility of being informed of their own FFI genotype; thus, the trial design had to include both carriers of the FFI mutation (10 subjects), and non-carriers (15 subjects), who were given placebo. Periodic clinical controls were performed on both groups by blinded examiners. The lack of surrogate outcome measures of treatment efficacy has required to compare the incidence of the disease in the treated group with a historical dataset during 10 years of observation. The trial is expected to end in 2023. Regardless of the clinical outcome, it will provide worthwhile knowledge on the disease. It also offers an important example of public engagement and collaboration to improve the quality of clinical science.</description><identifier>ISSN: 1933-6896</identifier><identifier>EISSN: 1933-690X</identifier><identifier>DOI: 10.1080/19336896.2022.2083435</identifier><identifier>PMID: 35737759</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>clinical trial ; disease incidence ; genetic prion diseases ; Humans ; Insomnia, Fatal Familial - drug therapy ; Insomnia, Fatal Familial - genetics ; Mutation ; patient engagement ; Prion Diseases - genetics ; Research Paper ; tetracyclines</subject><ispartof>Prion, 2022-12, Vol.16 (1), p.66-77</ispartof><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2022</rights><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2022 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-a1417623d362f0f061cc277d1b0984d42b02aee849de7d1e0cd024c8c31ff5d73</citedby><cites>FETCH-LOGICAL-c534t-a1417623d362f0f061cc277d1b0984d42b02aee849de7d1e0cd024c8c31ff5d73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235883/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235883/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27481,27903,27904,53770,53772,59120,59121</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35737759$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Forloni, Gianluigi</creatorcontrib><creatorcontrib>Roiter, Ignazio</creatorcontrib><creatorcontrib>Artuso, Vladimiro</creatorcontrib><creatorcontrib>Marcon, Manuel</creatorcontrib><creatorcontrib>Colesso, Walter</creatorcontrib><creatorcontrib>Luban, Elviana</creatorcontrib><creatorcontrib>Lucca, Ugo</creatorcontrib><creatorcontrib>Tettamanti, Mauro</creatorcontrib><creatorcontrib>Pupillo, Elisabetta</creatorcontrib><creatorcontrib>Redaelli, Veronica</creatorcontrib><creatorcontrib>Mariuzzo, Francesco</creatorcontrib><creatorcontrib>Boscolo Buleghin, Giulia</creatorcontrib><creatorcontrib>Mariuzzo, Alice</creatorcontrib><creatorcontrib>Tagliavini, Fabrizio</creatorcontrib><creatorcontrib>Chiesa, Roberto</creatorcontrib><creatorcontrib>Ambrosini, Anna</creatorcontrib><title>Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement</title><title>Prion</title><addtitle>Prion</addtitle><description>Engaging patients as partners in biomedical research has gradually gained consensus over the last two decades. They provide a different perspective on health priorities and help to improve design and outcomes of clinical studies. This paper describes the relationship established between scientists and members of a large family at genetic risk of very rare lethal disease, fatal familial insomnia (FFI). This interaction led to a clinical trial based on the repurposing of doxycycline - an antibiotic with a known safety profile and optimal blood-brain barrier passage - which in numerous preclinical and clinical studies had given evidence of its potential therapeutic effect in neurodegenerative disorders, including prion diseases like FFI. The design of this trial posed several challenges, which were addressed jointly by the scientists and the FFI family. Potential participants excluded the possibility of being informed of their own FFI genotype; thus, the trial design had to include both carriers of the FFI mutation (10 subjects), and non-carriers (15 subjects), who were given placebo. Periodic clinical controls were performed on both groups by blinded examiners. The lack of surrogate outcome measures of treatment efficacy has required to compare the incidence of the disease in the treated group with a historical dataset during 10 years of observation. The trial is expected to end in 2023. Regardless of the clinical outcome, it will provide worthwhile knowledge on the disease. It also offers an important example of public engagement and collaboration to improve the quality of clinical science.</description><subject>clinical trial</subject><subject>disease incidence</subject><subject>genetic prion diseases</subject><subject>Humans</subject><subject>Insomnia, Fatal Familial - drug therapy</subject><subject>Insomnia, Fatal Familial - genetics</subject><subject>Mutation</subject><subject>patient engagement</subject><subject>Prion Diseases - genetics</subject><subject>Research Paper</subject><subject>tetracyclines</subject><issn>1933-6896</issn><issn>1933-690X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>DOA</sourceid><recordid>eNp9kU1vEzEQhlcIREvhJ4B85JLWH-tdLwdEVQGtVAkOIHGzZu1x6uC1g70J6r_HIUlFL1zs0cw778zoaZrXjJ4zqugFG4To1NCdc8p5fZRohXzSnO7yi26gP54e4yo6aV6UsqJUDpyL582JkL3oezmcNuVrxi3G2W-RrO8gT2BSSEtvIJA5I8xTLRIfSdmMKzRzITCT7MtP4lImDuaqczD54GvgY0lT9PCOFOMxGiQQLVlvxuANwbiEJe7sXjbPHISCrw7_WfP908dvV9eL2y-fb64ubxdGinZeAGtZ33FhRccddbRjxvC-t2ykg2pty0fKAVG1g8WaRWos5a1RRjDnpO3FWXOz97UJVnqd_QT5Xifw-m8i5aWGPHsTUI-uHUXHJJeMtSjt0EMdgNKNzsDQq-r1fu9Vr5nQmnpGhvDI9HEl-ju9TFs9cCGVEtXg7cEgp18bLLOefDEYAkRMm6J5pxgVXcVSpXIvNTmVktE9jGFU7-DrI3y9g68P8Gvfm393fOg60q6CD3uBj5XeBL9TDlbPcB9Sdhmi8UWL_8_4A5EmwY8</recordid><startdate>20221231</startdate><enddate>20221231</enddate><creator>Forloni, Gianluigi</creator><creator>Roiter, Ignazio</creator><creator>Artuso, Vladimiro</creator><creator>Marcon, Manuel</creator><creator>Colesso, Walter</creator><creator>Luban, Elviana</creator><creator>Lucca, Ugo</creator><creator>Tettamanti, Mauro</creator><creator>Pupillo, Elisabetta</creator><creator>Redaelli, Veronica</creator><creator>Mariuzzo, Francesco</creator><creator>Boscolo Buleghin, Giulia</creator><creator>Mariuzzo, Alice</creator><creator>Tagliavini, Fabrizio</creator><creator>Chiesa, Roberto</creator><creator>Ambrosini, Anna</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20221231</creationdate><title>Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement</title><author>Forloni, Gianluigi ; Roiter, Ignazio ; Artuso, Vladimiro ; Marcon, Manuel ; Colesso, Walter ; Luban, Elviana ; Lucca, Ugo ; Tettamanti, Mauro ; Pupillo, Elisabetta ; Redaelli, Veronica ; Mariuzzo, Francesco ; Boscolo Buleghin, Giulia ; Mariuzzo, Alice ; Tagliavini, Fabrizio ; Chiesa, Roberto ; Ambrosini, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-a1417623d362f0f061cc277d1b0984d42b02aee849de7d1e0cd024c8c31ff5d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>clinical trial</topic><topic>disease incidence</topic><topic>genetic prion diseases</topic><topic>Humans</topic><topic>Insomnia, Fatal Familial - drug therapy</topic><topic>Insomnia, Fatal Familial - genetics</topic><topic>Mutation</topic><topic>patient engagement</topic><topic>Prion Diseases - genetics</topic><topic>Research Paper</topic><topic>tetracyclines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Forloni, Gianluigi</creatorcontrib><creatorcontrib>Roiter, Ignazio</creatorcontrib><creatorcontrib>Artuso, Vladimiro</creatorcontrib><creatorcontrib>Marcon, Manuel</creatorcontrib><creatorcontrib>Colesso, Walter</creatorcontrib><creatorcontrib>Luban, Elviana</creatorcontrib><creatorcontrib>Lucca, Ugo</creatorcontrib><creatorcontrib>Tettamanti, Mauro</creatorcontrib><creatorcontrib>Pupillo, Elisabetta</creatorcontrib><creatorcontrib>Redaelli, Veronica</creatorcontrib><creatorcontrib>Mariuzzo, Francesco</creatorcontrib><creatorcontrib>Boscolo Buleghin, Giulia</creatorcontrib><creatorcontrib>Mariuzzo, Alice</creatorcontrib><creatorcontrib>Tagliavini, Fabrizio</creatorcontrib><creatorcontrib>Chiesa, Roberto</creatorcontrib><creatorcontrib>Ambrosini, Anna</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Prion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Forloni, Gianluigi</au><au>Roiter, Ignazio</au><au>Artuso, Vladimiro</au><au>Marcon, Manuel</au><au>Colesso, Walter</au><au>Luban, Elviana</au><au>Lucca, Ugo</au><au>Tettamanti, Mauro</au><au>Pupillo, Elisabetta</au><au>Redaelli, Veronica</au><au>Mariuzzo, Francesco</au><au>Boscolo Buleghin, Giulia</au><au>Mariuzzo, Alice</au><au>Tagliavini, Fabrizio</au><au>Chiesa, Roberto</au><au>Ambrosini, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement</atitle><jtitle>Prion</jtitle><addtitle>Prion</addtitle><date>2022-12-31</date><risdate>2022</risdate><volume>16</volume><issue>1</issue><spage>66</spage><epage>77</epage><pages>66-77</pages><issn>1933-6896</issn><eissn>1933-690X</eissn><abstract>Engaging patients as partners in biomedical research has gradually gained consensus over the last two decades. They provide a different perspective on health priorities and help to improve design and outcomes of clinical studies. This paper describes the relationship established between scientists and members of a large family at genetic risk of very rare lethal disease, fatal familial insomnia (FFI). This interaction led to a clinical trial based on the repurposing of doxycycline - an antibiotic with a known safety profile and optimal blood-brain barrier passage - which in numerous preclinical and clinical studies had given evidence of its potential therapeutic effect in neurodegenerative disorders, including prion diseases like FFI. The design of this trial posed several challenges, which were addressed jointly by the scientists and the FFI family. Potential participants excluded the possibility of being informed of their own FFI genotype; thus, the trial design had to include both carriers of the FFI mutation (10 subjects), and non-carriers (15 subjects), who were given placebo. Periodic clinical controls were performed on both groups by blinded examiners. The lack of surrogate outcome measures of treatment efficacy has required to compare the incidence of the disease in the treated group with a historical dataset during 10 years of observation. The trial is expected to end in 2023. Regardless of the clinical outcome, it will provide worthwhile knowledge on the disease. It also offers an important example of public engagement and collaboration to improve the quality of clinical science.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>35737759</pmid><doi>10.1080/19336896.2022.2083435</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1933-6896
ispartof Prion, 2022-12, Vol.16 (1), p.66-77
issn 1933-6896
1933-690X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9235883
source Taylor & Francis Open Access; PubMed Central
subjects clinical trial
disease incidence
genetic prion diseases
Humans
Insomnia, Fatal Familial - drug therapy
Insomnia, Fatal Familial - genetics
Mutation
patient engagement
Prion Diseases - genetics
Research Paper
tetracyclines
title Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T17%3A01%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preventive%20pharmacological%20treatment%20in%20subjects%20at%20risk%20for%20fatal%20familial%20insomnia:%20science%20and%20public%20engagement&rft.jtitle=Prion&rft.au=Forloni,%20Gianluigi&rft.date=2022-12-31&rft.volume=16&rft.issue=1&rft.spage=66&rft.epage=77&rft.pages=66-77&rft.issn=1933-6896&rft.eissn=1933-690X&rft_id=info:doi/10.1080/19336896.2022.2083435&rft_dat=%3Cproquest_pubme%3E2681036377%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c534t-a1417623d362f0f061cc277d1b0984d42b02aee849de7d1e0cd024c8c31ff5d73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2681036377&rft_id=info:pmid/35737759&rfr_iscdi=true